Effects of levosimendan on cell viability in hepatocytes and LX-2 that were subjected peroxidation.

<p>C = control; Levo = levosimendan; ZVAD = Z-VAD.FMK (Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone), 25 mM; Rapa = rapamycin, 100 nM; 3-MA = 3-methyladenine, 10 mM; 5HD = 5 hydroxydecanoate, 1 μM; L-NAME = Nω-nitro-L-arginine methyl ester, 10 mM; MTT = 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; TBHP = tert-butyl hydroperoxide, 250 μM. In A, b, c, d, e, f, g, h, i, l, m, n, o <i>P</i> < 0.05 vs a; c, d, e, f, g, h, i, l, m, n, o <i>P</i> <0.05 vs b; d, e <i>P</i> <0.05 vs c; e <i>P</i> <0.05 vs d; g, i, m, n, o <i>P</i> <0.05 vs e. In B, b, c, e <i>P</i> <0.05 vs a; c, d, e <i>P</i> <0.05 vs b; d, e <i>P</i> <0.05 vs c; e <i>P</i> <0.05 vs d. In C and D, b, c, d, e <i>P</i> <0.05 vs a; d, e <i>P</i> <0.05 vs b, c; e <i>P</i> <0.05 vs d. The results obtained in hepatocytes and LX-2 are expressed as means of 5 or 4 independent experiments (%) ± SD (indicated by the bars), respectively.